Zhang Jie, Shi Guo-Ping
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Biochim Biophys Acta. 2012 Jan;1822(1):14-20. doi: 10.1016/j.bbadis.2010.12.012. Epub 2010 Dec 23.
Mast cells are critical effectors in the development of allergic diseases and in many immunoglobulin E-mediated immune responses. These cells exert their physiological and pathological activities by releasing granules containing histamine, cytokines, chemokines, and proteases, including mast cell-specific chymase and tryptase. Like macrophages and T lymphocytes, mast cells are inflammatory cells, and they participate in the pathogenesis of inflammatory diseases such as cardiovascular complications and metabolic disorders. Recent observations suggested that mast cells are involved in insulin resistance and type 2 diabetes. Data from animal models proved the direct participation of mast cells in diet-induced obesity and diabetes. Although the mechanisms by which mast cells participate in these metabolic diseases are not fully understood, established mast cell pathobiology in cardiovascular diseases and effective mast cell inhibitor medications used in pre-formed obesity and diabetes in experimental models offer hope to patients with these common chronic inflammatory diseases. This article is part of a Special Issue entitled: Mast cells in inflammation.
肥大细胞是过敏性疾病发展以及许多免疫球蛋白E介导的免疫反应中的关键效应细胞。这些细胞通过释放含有组胺、细胞因子、趋化因子和蛋白酶(包括肥大细胞特异性糜蛋白酶和组织蛋白酶)的颗粒来发挥其生理和病理活性。与巨噬细胞和T淋巴细胞一样,肥大细胞是炎症细胞,它们参与诸如心血管并发症和代谢紊乱等炎症性疾病的发病机制。最近的观察结果表明,肥大细胞与胰岛素抵抗和2型糖尿病有关。来自动物模型的数据证明肥大细胞直接参与饮食诱导的肥胖和糖尿病。尽管肥大细胞参与这些代谢疾病的机制尚未完全了解,但在心血管疾病中已确立的肥大细胞病理生物学以及在实验模型中用于肥胖症和糖尿病前期的有效肥大细胞抑制剂药物为患有这些常见慢性炎症性疾病的患者带来了希望。本文是名为《炎症中的肥大细胞》的特刊的一部分。